Cellular energy homeostasis is central to the maintenance of physiological function and the prevention of age-associated diseases. As global life expectancy rises, the importance of healthy aging has emerged as a critical focus in clinical and biomedical research. This review synthesizes current evidence on the mechanisms regulating energy homeostasis at the cellular level, epidemiology of age-related energy dysregulation, and highlights risk factors, clinical features, diagnostic approaches, and therapeutic strategies. Emphasis is placed on recent advances, emerging therapies, and guideline-based recommendations for optimizing cellular energy balance in older adults, providing clinicians with actionable insights for promoting longevity and functional independence.
Aging is characterized by a progressive decline in physiological reserves and increased susceptibility to chronic diseases. One of the pivotal elements underpinning healthy aging is the maintenance of cellular energy homeostasis, predominantly orchestrated by mitochondria, nutrient signaling pathways, and metabolic networks. Disruptions in these processes contribute to frailty, sarcopenia, neurodegeneration, and metabolic syndromes. Advancing our understanding of how energy homeostasis can be preserved is vital for clinicians aiming to support healthy aging in their patients, and for researchers developing targeted interventions.
The global population aged 65 and older is projected to double by 2050, amplifying the burden of age-associated morbidity. Epidemiological studies reveal a correlation between impaired cellular energy metabolism and the prevalence of age-related disorders such as Alzheimer’s disease, Parkinson’s disease, type 2 diabetes, and cardiovascular disease. Loss of energy homeostasis has been implicated in the pathogenesis of frailty, with population-based studies indicating that up to 15% of adults over 65 exhibit clinical frailty, largely attributed to mitochondrial dysfunction and metabolic inflexibility. The socioeconomic impact is substantial, driving increased healthcare utilization and reduced quality of life.
At the core of cellular energy homeostasis are mitochondria, which generate ATP via oxidative phosphorylation. With aging, mitochondrial DNA mutations accumulate, respiratory chain efficiency declines, and reactive oxygen species (ROS) production increases. Impaired mitophagy leads to the accumulation of dysfunctional mitochondria, further exacerbating energy deficits. Key nutrient-sensing pathways, including AMP-activated protein kinase (AMPK), sirtuins, and the mechanistic target of rapamycin (mTOR), become dysregulated with age, disrupting autophagy, protein synthesis, and metabolic flexibility. Chronic low-grade inflammation ("inflammaging") and insulin resistance further compromise cellular energy management. Emerging data also implicate impaired NAD+ metabolism and altered mitochondrial biogenesis as central contributors to age-related energy imbalance.
Multiple intrinsic and extrinsic factors predispose individuals to energy homeostasis disruption during aging. Genetic predisposition, persistent oxidative stress, sedentary lifestyle, chronic malnutrition, and comorbidities (e.g., diabetes, cardiovascular disease) are key contributors. Certain medications, environmental toxins, and sleep disturbances also exacerbate mitochondrial dysfunction. Gender, ethnicity, and socioeconomic status modulate risk through differential exposure to these factors. Recent genomic studies have identified polymorphisms affecting mitochondrial function and nutrient-sensing pathways as additional risk determinants.
Clinically, impaired cellular energy homeostasis manifests as fatigue, exercise intolerance, muscle weakness, cognitive decline, and increased vulnerability to stressors. In advanced stages, patients may develop sarcopenia, frailty, and falls. Subtle cognitive changes often precede overt neurodegeneration, with impaired energy supply to neurons implicated in the pathophysiology of dementia. Laboratory findings may include elevated lactate, markers of oxidative stress, and altered metabolomic profiles. Early recognition of these features is crucial for timely intervention.
Diagnosis of impaired cellular energy homeostasis requires a multifaceted approach. Clinical assessment should include functional evaluations (gait speed, grip strength), frailty indices, and cognitive screening. Laboratory investigations encompass metabolic panels, lactate levels, and markers of oxidative stress. Advanced techniques, such as muscle biopsies, mitochondrial respiration assays, and metabolomic profiling, provide mechanistic insights but are primarily research tools. Imaging modalities, including magnetic resonance spectroscopy (MRS), can noninvasively assess energy metabolism in tissues. Emerging biomarkers, such as circulating cell-free mitochondrial DNA and NAD+ metabolites, are under investigation for their diagnostic utility.
Management strategies aim to restore or preserve mitochondrial function and metabolic flexibility. Lifestyle interventions, notably regular aerobic and resistance exercise, are strongly supported by evidence and are cornerstone recommendations. Nutritional optimization, with emphasis on adequate protein, micronutrients (e.g., B vitamins, magnesium), and polyphenols, supports mitochondrial biogenesis and function. Pharmacological approaches include agents targeting mitochondrial dynamics (e.g., CoQ10, L-carnitine), antioxidants, and NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide). Addressing comorbidities, medication review, and management of polypharmacy are essential. Multidisciplinary approaches involving physical therapy, nutritionists, and geriatricians optimize patient outcomes.
Recent research has highlighted the therapeutic potential of senolytics agents that selectively clear senescent cells to improve mitochondrial function and energy homeostasis. Novel drugs targeting sirtuin pathways and mTOR inhibitors (e.g., rapalogs) have demonstrated efficacy in preclinical models of aging. Advances in gene therapy, mitochondrial transplantation, and the use of exogenous NAD+ boosters are under active investigation. Precision medicine approaches leveraging personalized metabolic profiling are emerging, aiming to tailor interventions based on individual risk and metabolic phenotype. Clinical trials are ongoing to evaluate the long-term safety and efficacy of these novel therapies.
Current geriatric and metabolic society guidelines emphasize early identification of frailty and metabolic dysfunction. Recommendations include routine screening for sarcopenia, tailored exercise prescriptions, comprehensive nutritional assessment, and minimization of polypharmacy. The incorporation of frailty indices into standard geriatric care is advocated. Consensus statements highlight the importance of multimodal interventions and patient education regarding lifestyle modifications. Research guidelines encourage the integration of metabolic biomarkers and advanced diagnostics in both clinical practice and research settings.
Preserving cellular energy homeostasis is foundational for healthy aging and the prevention of age-related morbidity. A mechanistic understanding of mitochondrial biology, risk stratification, and the implementation of evidence-based lifestyle and pharmacological interventions are essential strategies for clinicians. Ongoing research holds promise for novel therapies targeting the root causes of energy dysregulation. Multidisciplinary, guideline-driven approaches should be prioritized to optimize healthspan and functional independence in the aging population.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation